These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cancer and Leukemia Group B (CALGB). Kornblith AB J Natl Cancer Inst Monogr; 1996; (20):67-71. PubMed ID: 8750469 [No Abstract] [Full Text] [Related]
5. Childrens Cancer Group (CCG). MacLean WE J Natl Cancer Inst Monogr; 1996; (20):87-8. PubMed ID: 8750475 [No Abstract] [Full Text] [Related]
6. Radiation Therapy Oncology Group (RTOG). Wasserman T; Bruner D; Scott C J Natl Cancer Inst Monogr; 1996; (20):81-2. PubMed ID: 8750473 [No Abstract] [Full Text] [Related]
7. Quality of life in clinical cancer trials: experience and perspective of the European Organization for Research and Treatment of Cancer. Kiebert GM; Kaasa S J Natl Cancer Inst Monogr; 1996; (20):91-5. PubMed ID: 8750477 [No Abstract] [Full Text] [Related]
8. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous. Steensma DP J Clin Oncol; 2007 Mar; 25(9):1148; author reply 1148-9. PubMed ID: 17369584 [No Abstract] [Full Text] [Related]
11. Quality of life assessment in Southwest Oncology Group trials. Moinpour CM; Hayden KA; Thompson IM; Feigl P; Metch B Oncology (Williston Park); 1990 May; 4(5):79-84, 89; discussion 104. PubMed ID: 2143413 [TBL] [Abstract][Full Text] [Related]
12. Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group. Osoba D; Dancey J; Zee B; Myles J; Pater J J Natl Cancer Inst Monogr; 1996; (20):107-11. PubMed ID: 8750480 [TBL] [Abstract][Full Text] [Related]
13. Model for quality-of-life research from the Cancer and Leukemia Group B: the telephone interview, conceptual approach to measurement, and theoretical framework. Kornblith AB; Holland JC J Natl Cancer Inst Monogr; 1996; (20):55-62. PubMed ID: 8750467 [No Abstract] [Full Text] [Related]
14. Costs of quality-of-life research in Southwest Oncology Group trials. Moinpour CM J Natl Cancer Inst Monogr; 1996; (20):11-6. PubMed ID: 8750461 [TBL] [Abstract][Full Text] [Related]
15. Quality-of-life outcomes in oncology. Siddiqui F; Kachnic LA; Movsas B Hematol Oncol Clin North Am; 2006 Feb; 20(1):165-85. PubMed ID: 16580562 [TBL] [Abstract][Full Text] [Related]
16. "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials. Penel N; Clisant S; Lefebvre JL; Adenis A J Clin Oncol; 2009 Sep; 27(26):e105. PubMed ID: 19667257 [No Abstract] [Full Text] [Related]
17. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. Dilts DM; Sandler AB; Baker M; Cheng SK; George SL; Karas KS; McGuire S; Menon GS; Reusch J; Sawyer D; Scoggins M; Wu A; Zhou K; Schilsky RL; J Clin Oncol; 2006 Oct; 24(28):4553-7. PubMed ID: 17008694 [TBL] [Abstract][Full Text] [Related]
18. Ensuring the quality of quality of life data: the Southwest Oncology Group experience. Moinpour CM; Lovato LC Stat Med; 1998 Mar 15-Apr 15; 17(5-7):641-51. PubMed ID: 9549813 [TBL] [Abstract][Full Text] [Related]
19. Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. Osoba D; Bezjak A; Brundage M; Pater J; Value Health; 2007; 10 Suppl 2():S138-45. PubMed ID: 17995472 [TBL] [Abstract][Full Text] [Related]
20. Protocol information provides opportunity for patient safety and quality improvement. George TJ; Leather H J Clin Oncol; 2011 Jun; 29(18):e563. PubMed ID: 21576645 [No Abstract] [Full Text] [Related] [Next] [New Search]